U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07739914) titled 'Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)' on July 15.
Brief Summary: The overall aim of this study is nephroprotection based on a calcineurin inhibitor (CNI)-free therapy beyond year one after orthotopic liver transplantation (OLT) in highly pre-selected patients with low rejection risk.
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Liver Allograft
Liver Diseases
Liver Transplantation
Intervention:
DRUG: Everolimus
Patients in the intervention group will be switched to CNI-free mTORI-based immunosuppression (EVR 3-8ng/ml) with MMF (250-75...